Bracco is an international Group active in the healthcare sector and a leader in diagnostic imaging. The Group’s main products are contrast agents sold in over 100 countries, both directly and indirectly through branches, joint ventures and license and distribution agreements.
Research and Development (R&D) encompasses a wide range of roles focused on the innovation, development, and enhancement of products, technologies, and processes. Professionals in this field work to transform scientific knowledge into practical applications, ensuring that the organization's offerings are at the forefront of the industry. This job family is essential for driving growth, maintaining competitiveness, and addressing emerging market needs.
Background and Motivation
Contrast media injectors are safety-critical medical devices used in CT and MRI imaging. Verification of their performance is essential but remains largely manual, making testing time-consuming and prone to variability.
A robotic test system is already implemented and operational. The next step is to expand its capabilities: enabling it to autonomously execute test protocols, increase flexibility. This project focuses on advancing the existing robotic platform into an intelligent and configurable test automation system for contrast media injectors.
Objectives
- Program the existing robotic system to autonomously execute structured test protocols.
- Develop a flexible software framework to configure and run different test sequences.
- Expand the robot’s capabilities to cover additional test scenarios and edge cases.
- Quantify efficiency gains and reproducibility compared to manual testing.
Contract type:
InternshipIf you meet the requirements of this opportunity and would like to join an international group working to improve patients' lives, apply now!
At Bracco, we believe in the values of diversity and inclusion. We respect and celebrate the diversity of our people and their experiences, ensuring a fair opportunity for all.
We are #Bracco #JoinUs
What We Do
Bracco is an international Group active in the healthcare sector and a leader in diagnostic imaging. It has around 3,700 employees and annual total consolidated revenues of around 1,7 billion euros, 89% of which from international sales. In the R&D area, the company invests approximately 10% of reference turnover in the imaging diagnostics and medical devices sectors. The Group’s main products are contrast agents, medical substances used to improve the diagnostic accuracy of biomedical imaging and the care of patients affected by diseases of varying type and severity. Bracco offers an extensive and innovative portfolio of products and solutions for all diagnostic modalities completed by several medical devices and advanced administration systems for contrast imaging products in the fields of cardiology and radiology, developed by it’s American company ACIST. Since its foundation, Bracco has been a socially responsible company in each area of activity - in business as in every other context. Its subsidiary Bracco Imaging is one of the world’s leading companies in the diagnostic imaging field :X-Ray Imaging (including Computed Tomography-CT), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound, and Nuclear Medicine. The Company operates in over 110 markets: in North America through Bracco Diagnostics Inc. USA , and with an affiliate in Montreal (Canada); in Europe, with offices in all major countries; in Japan (BRACCO-EISAI). The Company also operates in South America, South Korea and China through its 70% controlled Joint Venture, Bracco Sine Pharmaceutical Corp. Ltd.







